Biopharma Update on the Novel Coronavirus: October 20
The Pharma Data
OCTOBER 19, 2020
Testing Therapies, Antivirals and Vaccines. For diseases that are very deadly without reliable therapies, it is considered unethical and very dangerous. In several studies , Gilead Sciences ’ remdesivir has shown that it can decrease the hospital stays of COVID-19 patients. They will require regulatory and ethical approval.
Let's personalize your content